ArticleeLife2022
Three-dimensional multi-site random access photostimulation (3D-MAP).
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A real-time all-optical interface for dynamic perturbation of neural activity during behavior.Cell reports methods · 2025Article
- High-throughput synaptic connectivity mapping using in vivo two-photon holographic optogenetics and compressive sensing.Nature neuroscience · 2025Article
- Compressive Fourier-Domain Intensity Coupling (C-FOCUS) enables near-millimeter deep imaging in the intact mouse brain in vivo.Research square · 2025Article
- Multiphoton Neurophotonics: Recent Advances in Imaging and Manipulating Neuronal Circuits.ACS photonics · 2025Review
- Scattering correction through Fourier-domain intensity coupling in two-photon microscopy (2P-FOCUS).Photonics research · 2025Article
- Three-dimensional random-access confocal microscopy with 3D remote focusing system.Communications engineering · 2024Article
- Modern Microscopic Approaches to Astrocytes.International journal of molecular sciences · 2023Review
- Computational optics for high-throughput imaging of neural activity.Neurophotonics · 2022Review
- Advances in computer-generated holography for targeted neuronal modulation.Neurophotonics · 2022Review
- Platforms for Optogenetic Stimulation and Feedback Control.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Optical control of neural ensemble activity is crucial for understanding brain function and disease, yet no technology can achieve optogenetic control of very large numbers of neurons at an extremely fast rate over a large volume. State-of-the-art multiphoton holographic optogenetics requires high-power illumination that only addresses relatively small populations of neurons in parallel. Conversely, one-photon holographic techniques can stimulate more neurons with two to three orders lower power, but with limited resolution or addressable volume. Perhaps most problematically, two-photon holographic optogenetic systems are extremely expensive and sophisticated which has precluded their broader adoption in the neuroscience community. To address this technical gap, we introduce a new one-photon light sculpting technique, three-dimensional multi-site random access photostimulation (3D-MAP), that overcomes these limitations by modulating light dynamically, both in the spatial and in the angular domain at multi-kHz rates. We use 3D-MAP to interrogate neural circuits in 3D and demonstrate simultaneous photostimulation and imaging of dozens of user-selected neurons in the intact mouse brain in vivo with high spatio-temporal resolution. 3D-MAP can be broadly adopted for high-throughput all-optical interrogation of brain circuits owing to its powerful combination of scale, speed, simplicity, and cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.